Krishna Institute of Medical Sciences will host analysts and institutional investors at Emkay Confluence 2026 on August 12, 2026, in Mumbai. The healthcare company announced the engagement schedule on August 4, 2026, providing stakeholders with an opportunity to interact with management regarding business operations and strategic direction. This group meeting format allows multiple investors to engage with company leadership simultaneously, ensuring broad dissemination of information.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Krishna Institute of Medical Sciences Limited submitted the intimation to both the Bombay Stock Exchange Ltd (BSE) and the National Stock Exchange (NSE). The company is listed under Scrip Code 543308 on BSE and Symbol KIMS on NSE, with ISIN INE967H01025.

Meeting Details

The event is scheduled as a group meeting, meaning it will not be a one-on-one session but rather a collective interaction with various market participants. The venue for Emkay Confluence 2026 is Mumbai, India.

The company noted that the schedule is subject to change due to exigencies, if any. Investors are advised to monitor official communications for any updates regarding timing or venue adjustments.

Compliance and Information Disclosure

Krishna Institute of Medical Sciences Limited explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the meeting. This assurance aligns with regulatory requirements designed to prevent insider trading and ensure fair access to material information for all market participants.

The disclosure was authorized by Nagajayanthi J.R., Company Secretary & Compliance Officer of Krishna Institute of Medical Sciences Limited. The notice was digitally signed on August 4, 2026, at 16:41:50 +05'30'.

What This Means for Investors

Analyst meetings serve as critical touchpoints for institutional investors and equity research analysts to gauge management sentiment and operational health. For Krishna Institute of Medical Sciences Limited, participating in Emkay Confluence 2026 signals its commitment to maintaining transparent communication with the investment community. While no specific financial results or strategic announcements were previewed in the filing, such events often provide context for recent performance trends or future growth initiatives within the healthcare sector.

Krishna Institute of Medical Sciences has published the audio recording of its investor conference call for Q1 FY27, providing stakeholders access to management commentary on the quarter's performance. The call was held on August 7, 2025, and the recording is now available on the company’s official website under the disclosures section for analysts' calls. This move ensures transparency and allows investors to review the detailed discussion regarding financial results and operational updates.

The filing was submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) in compliance with regulatory norms. Specifically, the disclosure aligns with Regulation 30 and Regulation 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These regulations mandate timely dissemination of material information to ensure fair access to data for all market participants.

Disciplinary Compliance

Krishna Institute of Medical Sciences Limited emphasized its adherence to listing obligations by formally notifying the exchanges. The audio file can be accessed via the company’s investor relations portal at https://www.kimshospitals.com/investors , specifically under the path: Disclosures under Regulation 46 > Analysts Calls schedule, PPT & Transcripts > Transcripts, Audio & Video Recordings > FY 26-27.

Corporate Governance

The communication was signed by Nagajayanthi J. R., who serves as the Company Secretary and Compliance Officer for Krishna Institute of Medical Sciences Limited. Her signature authenticates the disclosure, confirming that the information provided is accurate and complete as per the company’s records. The filing underscores the organization’s commitment to maintaining robust corporate governance standards and regulatory compliance.

Investors are advised to review the recording alongside other financial documents released during the quarter to gain a comprehensive understanding of the company’s strategic direction and financial health. The availability of such recordings supports informed decision-making by providing direct insights from management rather than relying solely on summarized reports.